Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Current Assets (2016 - 2025)

Historic Current Assets for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $332.0 million.

  • Regenxbio's Current Assets rose 592.57% to $332.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $332.0 million, marking a year-over-year increase of 592.57%. This contributed to the annual value of $278.0 million for FY2024, which is 1700.74% down from last year.
  • Regenxbio's Current Assets amounted to $332.0 million in Q3 2025, which was up 592.57% from $373.8 million recorded in Q2 2025.
  • Over the past 5 years, Regenxbio's Current Assets peaked at $518.8 million during Q4 2021, and registered a low of $278.0 million during Q4 2024.
  • Over the past 5 years, Regenxbio's median Current Assets value was $389.2 million (recorded in 2023), while the average stood at $392.2 million.
  • Its Current Assets has fluctuated over the past 5 years, first surged by 4742.44% in 2021, then tumbled by 2078.33% in 2025.
  • Over the past 5 years, Regenxbio's Current Assets (Quarter) stood at $518.8 million in 2021, then dropped by 19.82% to $416.0 million in 2022, then fell by 19.47% to $335.0 million in 2023, then dropped by 17.01% to $278.0 million in 2024, then grew by 19.41% to $332.0 million in 2025.
  • Its Current Assets was $332.0 million in Q3 2025, compared to $373.8 million in Q2 2025 and $313.2 million in Q1 2025.